Skip Navigation

JNCI Journal of the National Cancer Institute 2000 92(9):674-675; doi:10.1093/jnci/92.9.674
© 2000 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by McGuire, W. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McGuire, W. P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 92, No. 9, 674-675, May 3, 2000
© 2000 Oxford University Press

EDITORIALS

Confirmation of the "Old" Standard of Care for Ovarian Cancer and a Challenge

William P. McGuire

Correspondence to: William P. McGuire, M.D., The Gynecologic Oncology Center, Mercy Medical Center, Baltimore, MD 21202 (e-mail: wmcguire52@ aol.com).

The article by Piccart et al. (1) in this issue of the Journal confirms the importance of paclitaxel in the initial treatment of advanced ovarian cancer in a more heterogeneous group of patients (i.e., patients with stage IIB, IIC, III, or IV disease; 35% low-volume disease) than in the previously reported Gynecologic Oncology Group (GOG) trial (patients with stage IIIC or IV disease; 0% low-volume disease) (2). Perhaps, of more importance, it teaches us some important lessons about the politics of clinical trials. As Piccart et al. pointed out, this trial was designed, initiated, and completed in a short time period (<2 years) . . . [Full Text of this Article]

REFERENCES


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
S. De Placido, G. Scambia, G. Di Vagno, E. Naglieri, A. V. Lombardi, R. Biamonte, M. Marinaccio, G. Carteni, L. Manzione, A. Febbraro, et al.
Topotecan Compared With No Therapy After Response to Surgery and Carboplatin/Paclitaxel in Patients With Ovarian Cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) Randomized Study
J. Clin. Oncol., July 1, 2004; 22(13): 2635 - 2642.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. P. McGuire
Intraperitoneal Therapy for Ovarian Cancer: A Sacrifice Bunt
J. Clin. Oncol., February 15, 2001; 19(4): 921 - 923.
[Full Text] [PDF]